Botanix Pharmaceuticals Limited (AU:BOT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited has issued 4 million new shares following the exercise of options and has complied with regulatory requirements, enabling immediate trading of these shares. The company specializes in dermatology, with their flagship product Sofdra™, an FDA-approved treatment for axillary hyperhidrosis, marking a significant advancement for patients with this medical condition.
For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.